Ochsner Clinic Foundation

1. Novartis Pharmaceuticals Corporation $1,006,157 26 payments
2. Pfizer Inc. $771,008 62 payments
3. GlaxoSmithKline, LLC. $451,325 66 payments
4. Merck Sharp & Dohme Corporation $249,992 1 payment
5. Boston Scientific Corporation $127,145 132 payments
6. Avanos Medical $87,133 26 payments
7. Penumbra, Inc. $61,375 11 payments
8. FUJIFILM Medical Systems USA, Inc. $55,000 1 payment
9. InspireMD Ltd $39,786 2 payments
10. Astellas Pharma Global Development $37,962 13 payments

1. Acute Respiratory Illness Surveillance Aris By Monitoring Voice and Illness Symptom Changes Using A Mobile Application in A Lowinterventional Decentralized Study $402,192 1 payment
2. An Openlabel Multicenter Randomized Phase 3 Study of Firstline Encorafenib Plus Cetuximab With Or Without Chemotherapy Versus Standard of Care Therapy With A Safety Leadin of Encorafenib and Cetuximab Plus Chemotherapy in Participants With Metastatic Braf V600emutant Colorectal Cancer $294,859 58 payments
3. A phase II trial of pembrolizumab in combination with cisplatin or carboplatin and etoposide in chemotherapy naive patients with metastatic or unresectable high grade gastroenteropancreatic or lung excluding small cell neuroendocrine carcinoma $249,992 1 payment
4. A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed By Extended Treatment With Open-Label Remibrutinib $248,847 3 payments
5. An Open-Label, Randomized, Phase III Study Comparing 177Lu-Psma-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (Mhspc) $217,930 3 payments
6. A Randomized, Double-Blind, Phase 3 Comparison of Platinum-Based Thera $190,706 27 payments
7. A Randomized, Double-Blind, Placebo Controlled, 2-Arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome (Neptunus-1) $158,846 3 payments
8. A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the E $123,754 19 payments
9. A Randomized, Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL Pre-filled Syringe With 1 mL Pre-filled Syringe in Adult Participants With Autoimmune Disease $93,717 2 payments
10. A TWINSS Extension Trial to Evaluate the Safety and Tolerability of CFZ533 (Iscalimab) at Two Dose Levels Administered Subcutaneously in Patients With Sjgren's Syndrome $75,238 3 payments

1. Other $2,140 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.